PiCSO® Impulse System
Acute Myocardial Infarction (STEMI) during PCI
Key Facts
About Miracor Medical
Miracor Medical is a private, clinical-stage medical device company pioneering a novel interventional cardiology therapy called Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO). The company's lead PiCSO® Impulse System is designed as a first-line adjunct therapy during primary PCI to reduce infarct size and improve outcomes for heart attack patients, targeting a significant unmet need. With FDA IDE approval for a pivotal U.S. study secured in 2022 and a strong, experienced leadership team, Miracor is advancing towards key clinical milestones. The company is currently pre-revenue, having raised €24 million in 2020 to fund its clinical development programs.
View full company profileAbout Miracor Medical
Miracor Medical is a private, clinical-stage medical device company pioneering a novel interventional cardiology therapy called Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO). The company's lead PiCSO® Impulse System is designed as a first-line adjunct therapy during primary PCI to reduce infarct size and improve outcomes for heart attack patients, targeting a significant unmet need. With FDA IDE approval for a pivotal U.S. study secured in 2022 and a strong, experienced leadership team, Miracor is advancing towards key clinical milestones. The company is currently pre-revenue, having raised €24 million in 2020 to fund its clinical development programs.
View full company profile